Macbee Planet (7095) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
24 Jul, 2025Executive summary
Achieved record net sales and operating profit in FY04/2025, both increasing by 31% year-over-year, driven by expansion in the medical sector, large client deals, and LTV Marketing segment growth.
Continued business growth post-IPO, with a 52% CAGR in net sales and 65% CAGR in operating profit from 2020 to 2025.
Strategic focus on refining client portfolio, expanding PR services, executing M&A, and leveraging proprietary technology.
Transitioned to the Tokyo Stock Exchange Prime Market, began applying IFRS, and adopted a holding company structure.
LTV Marketing segment accounted for the majority of sales and profit, with strong new client acquisition.
Financial highlights
FY04/2025 net sales: ¥51,675 million (+31% YoY); operating profit: ¥4,639 million (+26% YoY); EBITDA: ¥5,241 million (+26% YoY).
Gross profit margin for FY04/2025 was 17.9%, with gross profit rising to ¥9,236 million.
Profit attributable to owners: ¥2,770 million in FY2025, forecasted to rise to ¥3,760 million in FY2026 (+22% YoY).
EPS for FY2025: ¥195.85, forecasted to increase to ¥270.99 in FY2026.
Annual dividend per share increased from ¥36 (FY2025) to a forecasted ¥55 (FY2026), post stock split.
Outlook and guidance
FY04/2026 net sales forecast: ¥61,000 million (+18% YoY); operating profit: ¥5,600 million (+21% YoY); profit attributable to owners: ¥3,760 million.
Focus on creating new consumer touchpoints, expanding own media, and continued client acquisition.
Targeting ¥70 billion in net sales and ¥7.5 billion in operating profit by FY04/2027.
Continued M&A activity planned, with investment of over ¥10 billion during the mid-term plan period.
Guidance considers economic uncertainties and market fluctuations.
Latest events from Macbee Planet
- Revenue and profit fell sharply year-over-year, but full-year guidance is maintained.7095
Q3 202613 Mar 2026 - Operating profit and margin fell as revenue growth slowed, leading to a downward forecast revision.7095
Q2 202611 Dec 2025 - Q1 revenue up 11% year-over-year, but profit fell sharply on higher ad costs; recovery forecast.7095
Q1 202611 Sep 2025 - Sales and profits more than doubled, with strong outlook and a 4-for-1 stock split ahead.7095
Q4 202424 Jul 2025 - Record sales and profit growth, led by medical and LTV Marketing, with a major share buyback.7095
Q1 202524 Jul 2025 - Sales up 30% in 1H, with strong growth in medical, finance, and LTV Marketing.7095
Q2 202524 Jul 2025 - Net sales and profits rose sharply, with upgraded guidance and strong LTV Marketing growth.7095
Q3 202524 Jul 2025